SCHEMBL17744437

SCHEMBL17744437

CC1CNCCN1c1nc2cc(Cl)cc(-c3ccccn3)c2o1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 4/20 0.39
▸ SLC6A2 P23975 2/20 0.39
▸ SLC6A4 P31645 2/20 0.39
▸ SLC6A3 Q01959 2/20 0.39
▸ LATS1 O95835 1/20 0.37
▸ ADORA2A P29274 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ GSK3B P49841 4/20 0.36
▸ WEE1 P30291 3/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ USP7 Q93009 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16391595 1.00 HTR2C (0.39) HTR2CSLC6A2SLC6A4SLC6A3LATS1
SCHEMBL16391959 0.89 LATS1 (0.37) HTR2CLATS1ADORA2AHTR7GSK3B
SCHEMBL16391962 0.89 LATS1 (0.37) HTR2CLATS1ADORA2AHTR7GSK3B
SCHEMBL17744480 0.89 LATS1 (0.37) HTR2CLATS1ADORA2AHTR7GSK3B
SCHEMBL17744559 0.89 LATS1 (0.37) HTR2CLATS1ADORA2AHTR7GSK3B
SCHEMBL17744299 0.89 LATS1 (0.37) HTR2CLATS1GSK3BWEE1HTR2A
SCHEMBL16391540 0.89 LATS1 (0.37) HTR2CLATS1GSK3BWEE1HTR2A
SCHEMBL16391457 0.88 HTR2C (0.38) HTR2CLATS1GSK3BWEE1USP7
SCHEMBL17744236 0.88 HTR2C (0.38) HTR2CLATS1GSK3BWEE1USP7
SCHEMBL17744261 0.87 HTR2C (0.43) HTR2CLATS1GSK3BWEE1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020718-B1 NOVEL PDE4 INHIBITOR MEIJI SEIKA PHARMA CO LTD (JP) 2018-12-26 — — EP claimed
US-9890142-B2 PDE4 inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-02-13 — — US claimed
US-9850235-B2 — — 2017-12-26 — — US claimed
US-20160159783-A1 PDE4 Inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-06-09 — — US claimed
EP-3020718-A1 NOVEL PDE4 INHIBITOR Meiji Seika Pharma Co., Ltd. (JP) 2016-05-18 — — EP claimed
EP-3020718-B1 NOVEL PDE4 INHIBITOR MEIJI SEIKA PHARMA CO LTD (JP) 2018-12-26 — — EP disclosed
US-9890142-B2 PDE4 inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-02-13 — — US disclosed
US-9850235-B2 — — 2017-12-26 — — US disclosed
US-20160159783-A1 PDE4 Inhibitor MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-06-09 — — US disclosed
EP-3020718-A1 NOVEL PDE4 INHIBITOR Meiji Seika Pharma Co., Ltd. (JP) 2016-05-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160159783-A1 PDE4 Inhibitor PDE4A, PDE4B, PDE3B HTR2C 3334/4885SLC6A2 1022/4885SLC6A4 419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback